

Complete List of Publications as of 31.03.2017**Peer Reviewed, Original Papers**

85. Pischke SE, Gustavsen A, Orrem HL, Egge KH, Courivaud F, Fontenelle H, Despont A, Bongoni AK, **Rieben R**, Tonnessen TI, Nunn MA, Scott H, Skulstad H, Barrat-Due A, Mollnes TE. Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function. *Basic Research in Cardiology* 2017, 112(3):20.
84. Zhang S, Wotzkow C, Bongoni AK, Shaw-Boden J, Siegrist M, Taddeo A, Blank F, Hofstetter W, **Rieben R***. Role of the plasma cascade systems in ischemia/reperfusion injury of bone. *Bone* 2017, 97:278-286.
*co-corresponding authors
83. Kamat P, Vandenberghe S, Christen S, Bongoni AK, Meier B, **Rieben R**, Khattab A. Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs. *PLoS ONE* 2016, 11(12): e0168541.
82. Zandi S, Tappeiner C, Pfister I, Despont A, **Rieben R**, Garweg J. Vitreal Cytokine Profile Differences Between Eyes With Epiretinal Membranes or Macular Holes. *Investigative Ophthalmology & Visual Science* 2016, 57(14):6320.
81. Bongoni AK, Klymiuk N, Wolf E, Ayares D, **Rieben R**, Cowan PJ. Transgenic Expression of Human Thrombomodulin Inhibits HMGB1-Induced Porcine Aortic Endothelial Cell Activation. *Transplantation* 2016, 100(9):1871-9.
80. Spirig A, Juon B, Banz Y, **Rieben R**, Vögelin E. Correlation Between Sonographic and In Vivo Measurement of A1 Pulleys in Trigger Fingers. *Ultrasound in Medicine & Biology* 2016, 42(7):1482-1490.
79. Ahrens HE, Petersen B, Herrmann D, Schwinzer R, Rataj D, Tiede A, Winkler M, Ramakers W, Bongoni A, **Rieben R**, Niemann H. Experimental approaches towards overcoming the acute vascular rejection during pig-to-primate xenotransplantation. *Züchtungskunde* 2016, 88(1):32-51.
78. Banz Y, Item GM, Vogt A, **Rieben R**, Candinas D, Beldi, G. Endothelial- and Platelet-derived Microparticles are generated during Liver Resection in Humans. *Journal of Investigative Surgery* 2016, 29(1):20-31.
77. Bongoni AK, Kiermeir D, Schnider J, Jenni HJ, Garimella PS, Bähr A, Klymiuk N, Wolf E, Ayares D, Vögelin E, Constantinescu M, Seebach J, **Rieben R**. Transgenic Expression of Human CD46 on Porcine Endothelium: Effect on Coagulation and Fibrinolytic Cascades During Ex Vivo Human-to-Pig Limb Xenoperfusions. *Transplantation* 2015, 99(10):2061-2069.
76. Zhang S, Duehrkop C, Plock J, **Rieben R**. Inhalation anesthesia of rats: Influence of the fraction of inspired oxygen on limb ischemia/reperfusion injury. *Laboratory Animals* 2015, 50(3):185-197.

75. Bongoni AK, Kiermeir D, Schnider J, Jenni HJ, Garimella PS, Bähr A, Klymiuk N, Wolf E, Ayares D, Voegelin E, Constantinescu MA, Seebach JD, **Rieben R**. Transgenic Expression of Human CD46 on Porcine Endothelium: Effect on Coagulation and Fibrinolytic Cascades During Ex Vivo Human-to-Pig Limb Xenoperfusions. *Transplantation* 2015, 99(10):2061-2069.
74. Egge KH, Thorgersen EB, Pischke SE, Lindstad JK, Anne Pharo A, Bongoni AK, **Rieben R**, Nunn MA, Barratt-Due A, Mollnes TE. Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. *Immunobiology* 2015, 220(8):999-1005.
73. Ahrens HE, Petersen B, Herrmann D, Lucas-Hahn A, Hassel P, Ziegler M, Kues WA, Baulain U, Baars W, Schwinzer R, Denner J, Rataj D, Werwitzke S, Tiede A, Bongoni AK, Garimella PS, Despont A, **Rieben R**, Niemann H. siRNA Mediated Knockdown of Tissue Factor Expression in Pigs for Xenotransplantation. *Am J Transplant* 2015, 15(5):1407-1414.
72. Bongoni AK, Kiermeir D, Denoyelle J, Jenni HJ, Burlak C, Seebach JD, Voegelin E, Constantinescu MA, **Rieben R**. Porcine extrahepatic vascular endothelial ASRG1 mediates platelet phagocytosis in vitro and in human-to-pig ex vivo xenoperfusion. *Transplantation* 2015, 99(4):693-701.
71. Gajanayake T, Olariu R, Leclère FM, Dhayani A, Yang Z, Bongoni AK, Banz Y, Constantinescu MA, Karp JM*, Vemula PK*, **Rieben R***, Vögelin E. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. *Sci Transl Med* 2014, 6(249):249ra110.
*co-corresponding authors
70. Bongoni AK, Kiermeir D, Jenni HJ, Bähr A, Ayares D, Klymiuk N, Wolf E, Voegelin E, Constantinescu MA, Seebach JD, **Rieben R**. Complement dependent early immunological responses during ex vivo xenoperfusion of hCD46/HLA-E double transgenic pig forelimbs with human blood. *Xenotransplantation* 2014, 21(3):230-243.
69. Dührkop C, **Rieben R**. Refinement of tourniquet-induced peripheral ischemia/reperfusion injury in rats: Comparison of 2h vs. 24h reperfusion. *Laboratory Animals* 2014, 48(2):143-154.
68. Dührkop C, Denoyelle J, Shaw S, **Rieben R**. Use of dextran sulfate in tourniquet-induced skeletal muscle reperfusion injury. *J Surg Res* 2014, 187(1):150-161.
67. Wünsch A, Bähr A, Bongoni AK, Kemter E, Blutke A, Baars W, Haertle S, Zakhartchenko V, Kurome M, Kessler B, Faber C, Abicht JM Reichart B, Wanke R, Schwinzer R, Nagashima H, **Rieben R**, Ayares D, Wolf E, Klymiuk N. Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs. *Transplantation* 2014, 97(2):138-147.
66. Schweizer DF, Schweizer R, Zhang S, Kamat P, Contaldo C, **Rieben R**, Eberli D, Giovanoli P, Erni D, Plock JA. Botulinum toxin A and B raise blood flow and increase survival of critically ischemic skin flaps. *J Surg Res* 2013, 184:1205–1213.
65. Bongoni AK, Kiermeir D, Jenni HJ, Wünsch A, Bähr A, Ayares D, Seebach JD, Wolf E, Klymiuk N, Constantinescu MA, Vögelin E, **Rieben R**. Activation of the Lectin Pathway of Complement in Pig-to-Human Xenotransplantation Models. *Transplantation* 2013, 96(9):791-799.

64. Khattab AA, Stieger S, Kamat PJ, Vandenberghe S, Bongoni AK, Stone GW, Seiler C, Meier B, Hess OM, **Rieben R**. Effect of pressure-controlled intermittent coronary sinus occlusion (PICSO) on myocardial ischemia and reperfusion in a closed-chest porcine model. *EuroIntervention* 2013, 9:398–406.
63. Barratt-Due A, Thorgersen EB, Egge K, Pischke S, Sokolov A, Hellerud BC, Lindstad JK, Pharo A, Bongoni AK, **Rieben R**, Nunn M, Scott H, Mollnes TE. Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis. *J Immunol* 2013, 191:819–827.
62. Bongoni AK, Lanz J, **Rieben R**, Banz Y. Development of a bead-based multiplex assay for the simultaneous detection of porcine inflammation markers using xMAP technology. *Cytometry* 2013, 83:636–647.
61. Ruder TD, Ebert LC, Khattab AA, **Rieben R**, Thali MJ, Kamat P. Edema is a sign of early acute myocardial infarction on post-mortem magnetic resonance imaging. *Forensic Sci Med Pathol* 2013, 9(4):501-505.
60. Müller S, Constantinescu MA, Kiermeir DM, Gajanayake T, Bongoni AK, Vollbach FH, Meoli M, Plock J, Jenni H, Banic A, **Rieben R***, Vögelin E. Ischemia/reperfusion injury of porcine limbs after extracorporeal perfusion. *J Surg Res* 2013, 181:170–182.
*corresponding author
59. Leclère FMP, Lewbart GA, **Rieben R**, Vögelin E. Microsurgery and liver research: *Lumbricus terrestris*, a reliable animal model for training? *Clin Res Hepatol Gastroenterol* 2013, 37:166–170.
58. Duehrkop C, Banz Y, Spirig R, Miescher S, Nolte MW, Spycher M, Smith RAG, Sacks SH, **Rieben R**. C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage. *PLoS ONE* 2013, 8(8):e72059.
57. Spirig R, Schaub A, Kropf A, Miescher S, Spycher MO, **Rieben R**. Reconstituted high-density lipoprotein modulates activation of human leukocytes. *PLoS One* 2013, 8(8), e71235.
56. Kamat P, Juon B, Jossen B, Gajanayake T, **Rieben R***, Vögelin E. Assessment of endothelium and inflammatory response at the onset of reperfusion injury in hand surgery. *J Inflamm (Lond)* 2012, 9:18-28.
*corresponding author
55. Veres-Nyeki KO, **Rieben R**, Spadavecchia C, Bergadano A. Pancuronium dose refinement in experimental pigs used in cardiovascular research. *Vet Anaest Analg* 2012, 39(5):529-532.
54. Banz Y, Hess OM, Meier P, Korchagina EY, Gordeeva EA, Robson SC, Gajanayake T, Csizmadia E, Mettler D, Haeberli A, Bovin NV, **Rieben R**. Evaluation of multimeric tyrosine-O-sulfate as a cytoprotectant in an in vivo model of acute myocardial infarction in pigs. *Cardiology* 2012, 121:59-70.
53. Jenni H, Rheinberger J, Czerny M, Gygax E, **Rieben R**, Krähenbühl E, Carrel T, Stalder M. Autotransfusion system or integrated automatic suction device in minimized extracorporeal circulation: influence on coagulation and inflammatory response. *Eur J Cardiothorac Surg* 2011, 39(5): e139-43.

52. Pochechueva T, Chinarev A, Spengler M, Korchagina E, Heinzelmann-Schwarz V, Bovin N, **Rieben R**. Multiplex suspension array for human anti-carbohydrate antibody profiling. *Analyst* 2011, 136:560-569.
51. Spirig R, Djafarzadeh S, Regueira T, Shaw SG, von Garnier C, Takala J, Jakob SM, **Rieben R**, Lepper PM. Effects of TLR agonists on the hypoxia-regulated transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions. *PLoS One* 2010, 5(6):e0010983.
50. Millard AL, Spirig R, Mueller NJ, Seebach JD, **Rieben R**. Inhibition of direct and indirect TLR-mediated activation of human NK cells by low molecular weight dextran sulfate. *Mol Immunol* 2010, 47(14):2349-2358.
49. Constantinescu MA, Knall E, Xu X, Kiermeir DM, Jenni HJ, Gyax E, **Rieben R**, Banic A, Vögelin E. Preservation of amputated extremities by extracorporeal blood perfusion; a feasibility study in a porcine model. *J Surg Res* 2011, 171:291-299.
48. Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, Hoefflerer L, **Rieben R**. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. *Vox Sang* 2009, 97(4):348-354.
47. Spirig R, Potapova I, Shaw-Boden J, Tsui J, **Rieben R**, Shaw SG. TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. *Mol Immunol* 2009, 46(15):3178-3182.
46. Banz Y, Gajanayake T, Matozan K, Yang Z, **Rieben R**. Dextran sulfate modulates MAP kinase signaling and reduces endothelial injury in a rat aortic clamping model. *J Vasc Surg* 2009, 50(1):161-170.
45. Gajanayake T, Sawitzki B, Matozan K, Korchagina EY, Lehmann M, Volk HD, **Rieben R**. Dextran Sulfate Facilitates Anti-CD4 mAb-Induced Long-Term Rat Cardiac Allograft Survival After Prolonged Cold Ischemia. *Am J Transplant* 2008, 8(6):1151-1162.
44. Spirig R, van Kooten C, Obregon C, Nicod L, Daha MR, **Rieben R**. The Complement Inhibitor Low Molecular Weight Dextran Sulfate Prevents TLR4-Induced Phenotypic and Functional Maturation of Human Dendritic Cells. *J Immunol* 2008, 181(2):878-890.
43. Banz Y, **Rieben R***, Zobrist C, Meier P, Shaw S, Lanz J, Carrel T, Berdat P. Addition of dextran sulfate to blood cardioplegia attenuates reperfusion injury in a porcine model of cardiopulmonary bypass. *Eur J Cardiothorac Surg* 2008, 34(3):653-660.
*corresponding author
42. Stüssi G, Müller RJ, Passweg J, Schanz U, **Rieben R**, Seebach JD. ABO blood group incompatible haematopoietic stem cell transplantation and xenograft rejection. *Swiss Med Wkly* 2007, 137(Suppl. 155):101S-108S.
41. Obukhova P, **Rieben R**, Bovin NV. Normal human serum contains high levels of anti Gal α 1-4GlcNAc antibodies. *Xenotransplantation* 2007, 14(6):627-635.
40. Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P, Haeberli A, Shaw S, Smith RA, **Rieben R**. Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. *Cardiovascular Research* 2007, 76(3):482-493.

39. Tanner H, Mohacsi P, Fuller-Bicer GA, **Rieben R**, Meier B, Hess O, Hullin R. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. *J Heart Lung Transplant* 2007, 26(6):622-629.
38. Baumann BC, Stüssi G, Huggel K, Hawley RJ, **Rieben R**, and Seebach JD. Reactivity of human natural antibodies to endothelial cells from Gal alpha(1,3) Gal-deficient pigs. *Transplantation* 2007, 83(2):193-201.
37. Banz Y, Hess OM, Robson SC, Mettler D, Meier P, Haeberli A, Csizmadia E, Korchagina EY, Bovin NV, **Rieben R**. Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischemia/reperfusion injury. *Eur Heart J* 2005, 26(21):2334-2343.
36. Stüssi G, Huggel K, Lutz HU, Schanz U, **Rieben R**, Seebach JD. Isotype-specific detection of ABO blood group antibodies using a novel, flow cytometric method. *Br J Haematol* 2005, 130(6):954-963.
35. Banz Y, Cung T, Korchagina EY, Bovin NV, Haeberli Y, **Rieben R**. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood. *Xenotransplantation* 2005, 12(6):434-443.
34. Baumann BC, Forte P, Hawley RJ, **Rieben R**, Schneider MKJ, Seebach JD. Lack of Gal α (1-3)Gal expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. *J Immunol* 2004, 172(10):6460-6467.
33. Laumonier T, Walpen AJ, Matozan KM, Korchagina EY, Bovin NV, Haeberli A, Mohacsi PJ, **Rieben R**. Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models. *Xenotransplantation* 2004 11(3):262-268.
32. Laumonier T, Mohacsi PJ, Matozan KM, Banz Y, Haeberli A, Korchagina EY, Bovin NV, Vanhove B, **Rieben R**. Endothelial Cell protection by dextran sulfate: A novel strategy to prevent acute vascular rejection in xenotransplantation. *Amer J Transpl* 2004, 4(2):181-187.
31. Walpen A, Laumonier T, Aebi C, Mohacsi PJ, **Rieben R**. Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum. *Xenotransplantation* 2004, 11(2):141-148.
30. Laumonier T, Walpen AJ, Maurus CF, Mohacsi PJ, Matozan KM, Korchagina EY, Bovin NV, Vanhove B, Seebach JD, **Rieben R**. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells. *Transplantation* 2003, 76(5):838-843.
29. Pochechueva TV, Ushakova NA, Preobrazhenskaya ME, Nifant'ev NE, Tsvetkov YE, Sablina MA, Tuzikov AB, Bird MI, **Rieben R**, Bovin NV. P-selectin blocking potency of multimeric tyrosine sulfates in vitro and in vivo. *Bioorg Med Chem Lett* 2003, 13(10):1709-1712.
28. Tsvetkov DE, Cheshev, PE, Tuzikov AB, Chinarev AA, Pazynina GV, Sablina MA, Gambaryan AS, Bovin NV, **Rieben R**, Shashkov AS, Nifant'ev NE. Neoglycoconjugates based on dendrimers poly(aminoamides). *Russian Journal of Bioorganic Chemistry* 2002, 28(6):470-486.

27. Pierson RN 3rd, Loyd JE, Goodwin A, Majors D, Dummer JS, Mohacsi P, Wheeler A, Bovin N, Miller GG, Olson S, Johnson J, **Rieben R**, Azimzadeh A. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. *Transplantation* 2002, 74(1):79-84.
26. Roos A, **Rieben R**, Faber-Krol MC, Daha MR. IgM-enriched human intravenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies. *Xenotransplantation* 2003, 10(6):596-605.
25. Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen H-U, Zürcher-Zenkhusen R, **Rieben R**, Devay J, Hack CE, Lämmle B, Wuillemin WA. C1-inhibitor in patients with severe sepsis or septic shock: beneficial effect on renal dysfunction. *Crit Care Med* 2002, 30(8):1722-1728.
24. Walpen AJ, Mohacsi PJ, Frey C, Roos A, Daha MR, **Rieben R**. Activation of complement pathways in xenotransplantation: an in vitro study. *Transplant Immunol* 2002, 9(2-4):271-280.
23. Mohacsi P, **Rieben R**, Sigurdsson G, Tschanz HU, Schaffner T, Nydegger UE, Carrel T. Successful management of a B-type cardiac allograft into an O-type man with 3^{1/2} year clinical follow-up. *Transplantation* 2001, 72(7):1328-1330.
22. Basker M, Alwayn IPJ, Buhler L, Harper D, Abraham S, Kruger Gray H, Awwad M, Down J, **Rieben R**, White-Scharf ME, Sachs DH, Thall A, Cooper DKC. Clearance of mobilized porcine peripheral blood progenitor cells is delayed by depletion of the phagocytic reticuloendothelial system in baboons. *Transplantation* 2001, 72(7):1278-1285.
21. Gerber B, Tinguely C, Bovin NV, **Rieben R**, Nydegger UE. Differences between synthetic oligosaccharide immunoabsorbents in depletion capacity for xenoreactive anti-Gal α 1-3Gal antibodies from human serum. *Xenotransplantation* 2001, 8(2):106-114.
20. Fiorante P, Banz Y, Mohacsi PJ, Kappeler A, Wuillemin WA, Macchiarini P, Roos A, Daha MR, Schaffner T, Haeberli A, Mazmanian GM, **Rieben R**. Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models. *Xenotransplantation* 2001, 8(1):24-35.
19. **Rieben R**, Bovin NV, Korchagina EY, Oriol R, Nifant'ev NE, Tsvetkov DE, Daha MR, Mohacsi PJ, Joziassse DH. Xenotransplantation: in vitro analysis of synthetic α -galactosyl inhibitors of human anti-Gal α 1-3Gal IgM and IgG antibodies. *Glycobiology* 2000, 10(2):141-148.
18. Buonomano R, Tinguely C, **Rieben R**, Mohacsi PJ, Nydegger UE. Quantitation and characterization of anti-Gal α 1-3Gal antibodies in sera of 200 healthy persons. *Xenotransplantation* 1999, 6(3):173-180.
17. Tsvetkov DE, Cheshev PE, Tuzikov AB, Pzynina GV, **Rieben R**, Bovin NV, Nifant'ev NE. Synthesis of neoglycoconjugate dendrimers. *Mendeleev Commun* 1999, 47-50.
16. **Rieben R**, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. *Blood* 1999, 93(3):942-951.

15. Macchiarini P, Oriol R, Azimzadeh A, de Montpreville V, **Rieben R**, Bovin N, Dartevelle P. Evidence of human non-alpha Gal antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. *J Thorac Cardiovasc Surg* 1998, 116(5):831-843.
14. Uetz-von Allmen E, Sturzenegger M, **Rieben R**, Rihs F, Frauenfelder A, Nydegger UE. Anti-ganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. *Eur Neurol* 1998, 39(2):103-110.
13. Macchiarini P, Mazmanian GM, Oriol R, de Montpreville V, Dulmet E, Fattal S, Libert JM, Dubin S, Nochy D, **Rieben R**, Dartevelle P. Ex-vivo lung model of pig-to-human hyperacute xenograft rejection. *J Thorac Cardiovasc Surg* 1997, 114(3):315-325.
12. **Rieben R**, Korchagina EY, Bovin NV, Daha MR. Specificity of monoclonal antibodies against ABH- and related structures tested by ELISA with synthetic glycoconjugates. *Transf Clin Biol* 1997, 1:47-54.
11. Friedli F, **Rieben R**, Wegmüller E, Moerenhout M, Nydegger UE. Normal levels of allo- but increased levels of potentially autoreactive antibodies against ABO histo-blood group antigens in AIDS patients. *Clin Immunol Immunopathol* 1996, 80(1):96-100.
10. **Rieben R**, Frauenfelder A, Nydegger UE. Spectrotype analysis of human ABO antibodies: evidence for different clonal heterogeneity of IgM, IgG, and IgA antibody populations. *Vox Sang* 1996, 70:104-111.
9. **Rieben R**, von Allmen E, Korchagina EY, Nydegger UE, Neethling, FA, Kujundzic M, Koren E, Bovin NV, Cooper DKC. Detection, immunoabsorption, and inhibition of cytotoxic activity of anti-alpha Gal antibodies using newly developed substances with synthetic Gal alpha1-3 Gal disaccharide epitopes. *Xenotransplantation* 1995, 2:98-106.
8. **Rieben R**, Korchagina EY, von Allmen E, Kremer Hovinga J, Lämmle B, Jungi T, Bovin NV, Nydegger UE. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. *Transplantation* 1995, 60(5):425-430.
7. von Allmen E, **Rieben R**, Nydegger UE. Development of a C1q-ABO-ELISA to measure C1 binding by human anti-A alloantibodies. *J Immunol Methods* 1994, 171(1):85-92.
6. Auf der Maur C, Hodel M, Nydegger UE, **Rieben R**. Age-dependency of ABO histo-blood group antibodies - reexamination of an old dogma. *Transfusion* 1993, 33(11):915-918.
5. **Rieben R**, Tucci M, Nydegger UE, Zubler RH. Self tolerance to human-A and human-B histo-blood group antigens exists at the B-cell level and cannot be broken by potent polyclonal B-cell activation in vitro. *Eur J Immunol* 1992, 22(10):2713-2717.
4. **Rieben R**, Frauenfelder A, Nydegger UE. Naturally occurring ABO antibodies - long-term stable, individually distinct anti-A IgG spectrotypes. *Eur J Immunol* 1992, 22(8):2129-2133.
3. Hasler CR, **Rieben R**, Buchs JP, Nydegger UE. Comparison between the levels of anti-A/B IgM/G antibodies in paired mother/child serum samples. *Transfus Sci* 1992, 13(1):113-118.
2. **Rieben R**, Buchs JP, Flückiger E, Nydegger UE. Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categories. *Transfusion* 1991, 31(7):607-15.

1. **Rieben R**, Blaser K. Quantification of IgG and IgG4 antibodies to bee venom phospholipase A2 by competitive inhibition in ELISA. *J Immunol Methods* 1989, 119(1):1-8.

Reviews, Book Sections, Case Reports, Comments

24. Puga Yung GL, **Rieben R**, Bühler L, Schuurman HL, Seebach J. Xenotransplantation: Where do we stand in 2016? *Swiss Medical Weekly* 2017, 147:w14403.
23. Cowan P, **Rieben R**. Modifying the Glycome in Pigs for Xenotransplantation. *Transplantation* 2016, 100(3):485-486.
22. Duehrkop C, **Rieben R**. Ischemia/reperfusion injury: Effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition. *Biochem Pharmacol* 2014, 88(1):12–22.
21. Banz Y, **Rieben R**. Role of complement and perspectives for intervention in ischemia-reperfusion damage. *Annals of Medicine* 2012, 44(3):205-217.
20. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, **Rieben R**. Intravenous immunoglobulins – understanding properties and mechanisms. *Clin Exp Immunol* 2009, 158(Suppl 1):2-13.
19. Spirig R, Gajanayake T, Korsgren O, Nilsson B, **Rieben R**. Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. *Mol Immunol* 2008, 45(16):4084-4094.
18. Banz Y, **Rieben R**. Exploring natural anticoagulation by endothelial cells: A novel *in vitro* model. *ALTEX* 2007, 24(special issue):9-11.
17. Banz Y, **Rieben R**. Exploring the natural anticoagulation by endothelial cells: A novel *in vitro* model. *3R-Info-Bulletin* no. 34, January 2007.
16. Stüssi G, Müller RJ, Passweg J, Schanz U, **Rieben R**, Seebach JD. ABO blood group incompatible hematopoietic stem cell transplantation and xenograft rejection. *Swiss Med Wkly* 2007, 137(1-2):13-20.
15. Banz Y, **Rieben R**. Endothelial cell protection in xenotransplantation: looking after a key player in rejection. *Xenotransplantation* 2006, 13(1):19-30.
14. Nydegger UE, **Rieben R**. ABO-, nicht aber HLA-Gewebemerkmale schaffen es in die Tagespresse. *Schweiz Med Forum* 2005, 5:1283–1284.
13. Nydegger UE, Tevaearai H, Berdat P, **Rieben R**, Carrel T, Mohacsi P, Flegel WA. Histo-blood group antigens as allo- and autoantigens. *Ann N Y Acad Sci* 2005, 1050:40-51.
12. **Rieben R**, Seebach JD. Xenograft rejection: IgG(1), complement and NK cells team up to activate and destroy the endothelium. *Trends Immunol* 2005, 26(1):2-5.
11. Nydegger UE, **Rieben R**, Carrel T, Mohacsi P. Solid organ transplantation across the ABO histo-blood group barrier: a case report. *Transplant Proc.* 2004, 36:1554-7.
10. Nydegger UE, **Rieben R**, Mohacsi PJ. Current precision of immunological extracorporeal plasma treatment. *Transfus Apheresis Sci* 2001, 24(1):39-47.
9. **Rieben R**. Xenotransplantation – Beteiligungserfahrung Biotech, 4. EU-Forschungsrahmenprogramm. *Euroscope-CH* 2000, 79:10-11.

8. **Rieben R.** Xenotransplantationsforschung in der Schweiz - Plädoyer für eine interdisziplinäre Zusammenarbeit. In: Potential and risk of xenotransplantation / Potential und Risiken der Xenotransplantation - Was Experten dazu meinen (Seebach JD, Candinas D, Largiader F, eds.) Luce Verlag, Murten 2000; pp. 158–163.
7. Nydegger UE, **Rieben R**, Lämmle B. Biocompatibility in transfusion medicine. *Transfusion Sci* 1996, 17(4): 10-15.
6. Nydegger UE, **Rieben R**. Combined use of plasma exchange and intravenous immunoglobulins. *Ann Med Int (Paris)* 1994;145(5):287-292.
5. Zubler RH, Tucci A, **Rieben R**, Matthes T, Nydegger UE. Quantification of autoreactive lymphocytes in health and disease. In: Autoimmunity: Physiology and Disease (Cautinho A and Kazatchkine MD, eds.) Wiley-Liss Inc., New York 1994; pp. 173-190.
4. Nydegger UE, **Rieben R**, Kazatchkine MD. Intravenöse Immunglobulintherapie als Beeinflussungsmöglichkeit von autoimmunen Prozessen. In: Infektionen und Autoimmunerkrankungen II: Therapie mit Immunglobulinen und deren Derivaten (Salama A, Kurrle R eds.) Universitätsverlag Jena 1993; pp 15-27.
3. Nydegger U, **Rieben R**. Nouveaux aspects immunologiques et cliniques des groups sanguins ABO. *Médecine et Hygiène* 1992;50:1334-1337.
2. Nydegger UE, **Rieben R**, Aeschbacher B. Biocompatibility of apheresis harness. *Transfus Sci* 1990;11(1):43-54.
1. Nydegger UE, **Rieben R**, Jungi TW. Synergy between plasma exchange and intravenous immunoglobulin. In: Nydegger UE, ed. Therapeutic Hemapheresis in the 1990's. Basel: Karger, 1990: 31-50. (Hässig A, Lundsgaard-Hansen P, eds. Current Studies in Hematology and Blood Transfusion; Vol 57).

Published Abstracts, Letters

97. Zhang S, Shaw J, Banz Y, Bongoni AK, Taddeo A, Spirig R, Nolte MW, Cowan P, **Rieben R**. Effects of C1-INH on complement deposition and endothelial cell activation in a rat hind limb ischemia/reperfusion injury model. *Immunobiology*, 2016, 221(10):1163
96. Sfriso R, Zhang S, Bichsel CA, Guenat OT, **Rieben R**. A vessel-like microfluidic system to study complement and coagulation in the context of xenotransplantation. *Immunobiology*, 2016, 221(10):1175
95. Sfriso R, Klymiuk N, Wuensch A, Seebach JD, Wolf E, **Rieben R**. Activation of complement and coagulation in xenotransplantation: Effect of growth hormone receptor knockout on porcine aortic endothelial cells. *Immunobiology*, 2016, 221(10):1174-1175
94. Abdelhafez M, Shaw J, Sutter D, Schnider J, Jenni H, Vögelin E, Constantinescu MA, **Rieben R**. The protective role of C1-INH on ischemia reperfusion injury in a porcine limb amputation and reperfusion model. *Immunobiology* 2016, 221(10):1164-1165
93. Bongoni AK, Cowan P, Kiermeir D, Schnider J, Jenni HJ, Garimella PS, Bähr A, Klymiuk N, Wolf E, Ayares D, Seebach J, Vögelin E, Constantinescu M, **Rieben R**. Effects of Transgenic Human Cd46-Mediated Complement Inhibition on Coagulation and Fibrinolysis During Ex Vivo Human-to-Pig Limb Xenoperfusion. *Transplantation* 2015, 99(11):25-25
92. Bongoni AK, Garimella P, Klymiuk N, Wolf E, Ayares D, Spirig R, **Rieben R**. Attenuation of high mobility group box 1 (HMGB1)-mediated proinflammatory responses by transgenic expression of human thrombomodulin on pig cells. *Xenotransplantation* 2015, 22:65-65
91. Bongoni AK, Wünsch A, Klymiuk N, Wolf E, Ayares D, **Rieben R**, Cowan P. Transgenic Expression of Human Thrombomodulin on Porcine Endothelial Cells Inhibits High Mobility Group Box 1 (Hmgb1) Induced Innate Immune Responses. *Transplantation* 2015, 99(11):24-24
90. Garimella PS, Bongoni AK, Schnider J, Kiermeir D, Jenni HJ, Bähr A, Klymiuk N, Wolf E, Ayares D, Vögelin E, Constantinescu MA, **Rieben R**. A new xenoantigen: human natural IGM antibodies bind to non-muscular myosin heavy chain type II on porcine endothelial cells. *Xenotransplantation* 2015, 22:84-84
89. Garimella PS, Bongoni AK, Schnider J, Kiermeir D, Jenni HJ, Bähr A, Klymiuk N, Wolf E, Ayares D, Vögelin E, Constantinescu MA, **Rieben R**. A New Xenoantigen: Human Natural Igm Antibodies Bind to Non-Muscular Myosin Heavy Chain Type Ii on Porcine Endothelial Cells. *Transplantation* 2015, 99(11):135-135
88. Sfriso R, Garimella PS, Yung GP, Klymiuk N, Wolf E, Ayares D, Seebach JD, **Rieben R**. Functional evaluation of immortalized porcine endothelial cells in a whole blood clotting assay. *Xenotransplantation* 2015, 22:66-66
87. Sfriso R, Garimella PS, Yung GP, Klyiuk N, Wolf E, Ayares D, Seebach JD, **Rieben R**. Functional Evaluation of Immortalized Porcine Endothelial Cells in a Whole Blood Clotting Assay. *Transplantation* 2015, 99 (11):106-106
86. Taddeo A, Denoyelle J, Olariu R, Leclere FM, Gajanayake T, Vögelin E, **Rieben R**. Intra-Graft Delivered High-Dose Immunosuppression as Potential Therapy in Vascularized Composite Allograft Transplantation. *Transplantation* 2015, 99(11): 37:37

85. Zhang S, Wotzkow C, Siegrist M, Hofstetter W, **Rieben R**. Role of the complement system in a rat model of bone ischemia/reperfusion injury. *Molecular Immunology* 2015, 67(1):197-197
84. Wuensch A, Baehr A, Bongoni AK, Kemter E, Blutke A, Baars W, Haertle S, Zakhartchenko V, Kurome M, Kessler B, Faber C, Reichart B, Wanke R, Schwinzer R, Nagashima H, **Rieben R**, Ayares D, Wolf E, Klymiuk N. Endothelial-specific expression of biological active human thrombomodulin in single-transgenic pigs and pigs with multiple genetic modifications. *Xenotransplantation* 2013, 20:346–346.
83. Yung GP, Pradier A, Madelon N, Millard AL, Bongoni A, Constantinescu M, Kiermeir D, Bähr A, Klymiuk N, **Rieben R**, Seebach JD. Reduction of human NK cell recruitment by transgenic HLA-E expression in a model of ex vivo xenogeneic pig-limb perfusion. *Xenotransplantation* 2013, 20:364–365.
82. Bongoni AK, Kiermeir D, Gajanayake T, Jenni H, Bähr A, Wuensch A, Ayares D, Seebach JD, Wolf E, Klymiuk N, Voegelin E, Constantinescu MA, **Rieben R**. ASGR1 expressed by porcine aortic endothelial cells mediates human platelet phagocytosis in vitro as well as during ex vivo pig-to-human porcine forelimb xenoperfusion. *Xenotransplantation* 2013, 20:360–360.
81. Bongoni AK, Kiermeir D, Jenni H, Wuensch A, Bähr A, Ayares D, Seebach JD, Wolf E, Klymiuk N, Constantinescu MA, Voegelin E, **Rieben R**. Activation of the lectin pathway of complement in pig-to-human xenotransplantation models. *Xenotransplantation* 2013, 20:365–365.
80. Bongoni AK, Kiermeir D, Constantinescu MA, Jenni H, Bähr A, Ayares D, Voegelin E, Klymiuk N, Seebach JD, **Rieben R**. Ex vivo xenoperfusion of (hCD46 & HLA-E)-double transgenic porcine forelimbs with whole, heparinized human blood: Study of early immunological responses. *Xenotransplantation* 2013, 20:368–368.
79. Abicht JM, Mayr T, Guethoff S, Bongoni A, **Rieben R**, Klymiuk N, Baehr A, Wuensch A, Petersen B, Bauer A, Reichart B, Fan JP, Thormann M, Ayares D, Brenner P. Ex-vivo perfusion of multiple genetically modified pig hearts. *Xenotransplantation* 2013, 20:359–359.
78. Duehrkop C, Banz Y, Spirig R, Miescher S, Nolte MW, Spycher M, Sacks SH, Smith RAG, **Rieben R**. C1 esterase inhibitor protects against peripheral ischemia/reperfusion injury and distant lung damage. *Mol Immunol* 2013, 56:288–288.
76. Egge KH, Thorgersen EB, Lindstad JK, Pharo AM, Bongoni AK, **Rieben R**, Barratt-Due A, Mollnes TE. Combined inhibition of C5 and CD14 attenuates organ inflammation in porcine *Escherichia coli* sepsis. *Mol Immunol* 2013, 56:246–246.
75. Gajanayake T, Olariu R, Leclere F, Vemula P, Yang Z, Bongoni A, Banz Y, Constantinescu M, Voegelin E, **Rieben R**. Complement activation in vascularized composite allotransplantation. *Mol Immunol* 2013, 56:283–283.
74. Duehrkop C, **Rieben R**. Effect of low molecular weight dextran sulfate on tourniquet-induced limb ischemia/reperfusion injury and distant lung damage. *Mol Immunol* 2013, 56:288–288.
73. Duehrkop C, Banz Y, Spirig R, Miescher S, Nolte MW, Spycher M, **Rieben R**. Effects of C1 esterase inhibitor on distant organ damage induced by ischemia/reperfusion injury of the lower extremity. *Mol Immunol* 2013, 56:288–289.

72. Bongoni AK, Kiermeir D, Jenni H, Constantinescu MA, Voegelin E, **Rieben R**. IgM-mediated activation of the lectin pathway of complement in pig-to-human xenotransplantation models. *Mol Immunol* 2013, 56:269–269.
71. Bongoni AK, Kiermeir D, Constantinescu MA, Jenni H, Baehr A, Ayares D, Voegelin E, Klymiuk N, Seebach J, **Rieben R**. Study of early immunological responses during ex vivo xenoperfusion of (hCD46 and HLA-E)-double transgenic porcine limbs with whole, heparin anti-coagulated human blood. *Mol Immunol* 2013, 56:306–306.
70. Pradier A, Millard A-L, Bongoni A, Constantinescu M, Kiermeir D, Schneider M, Baehr A, Klymiuk N, **Rieben R**, Seebach JD. Ex vivo perfusion of HLA-E/CD46 transgenic pig limbs with human blood: evaluation of NK cell recruitment. *Xenotransplantation* 2013, 20:53–54.
69. Bongoni AK, **Rieben R**. IgM-dependent activation of the lectin pathway of complement in xenotransplantation. *Xenotransplantation* 2013, 20:63–63.
68. Duehrkop-Sisewitsch C, Banz Y, Spirig R, Miescher S, Nolte MW, Spycher M, **Rieben R**. Effects of C1 esterase inhibitor on attenuation of ischemia/reperfusion injury in a rat hind limb model. *Immunobiology* 2012, 217:1165–1166.
67. Bongoni A, Constantinescu M, Kiermeir D, Pradier A, Millard AL, Schneider M, Bähr A, Ayares D, Voegelin E, Seebach J, Klymiuk N, **Rieben R**. Ex vivo xenoperfusion of CD46 & HLA-E double transgenic pig limbs: Effect of transgenic expression of human CD46 and role of natural IgM & mannose binding lectin pathway. *Xenotransplantation* 2011, 18(5):305.
66. Pradier A, Nobari RH, Millard AL, Bongoni A, Constantinescu M, Kiermeir D, Schneider M, Bähr A, Klymiuk N, **Rieben R**, Seebach JD. Novel experimental models to test human NK cell recruitment to porcine endothelium and their role in cellular xenograft rejection. *Xenotransplantation* 2011, 18(5):273.
65. Kiermeir, D, Voegelin E, Bähr A, Ayares D, Klymiuk N, Bongoni A, **Rieben R**, Jenni HJ, Constantinescu M. Extracorporeal human blood perfusion of CD46 & HLA-E double transgenic pig limbs: A technique for the study of immunologic effects in composite tissue xenografts. *Xenotransplantation* 2011, 18(5):304.
64. Kamat J, Juon B, Jossen B, Gajanayake, TG, **Rieben R**, Voegelin EV. No involvement of antibodies and complement in the onset of tourniquet-induced ischemia/reperfusion injury in hand surgery. *Mol Immunol* 2011, 48(14):1694.
63. Kamat J, Broillet A, Helbert A, Bettinger T, Schneider M, **Rieben R**. Antibodies and complement are deposited in viable myocardium in a porcine model of acute coronary syndrome. *Mol Immunol* 2011, 48(14):1671.
62. Bongoni A, Constantinescu M, Kiermeir D, Pradier A, Millard AL, Bähr A, Voegelin E, Seebach J, Klymiuk N, **Rieben R**. Ex vivo xenoperfusion of CD46 & HLA-E double transgenic pig limbs: Effect of transgenic expression of human CD46. *Mol Immunol* 2011, 48(14):1671-1672.
61. Kamat P, Broillet A, Helbert A, Bettinger T, Tranquart F, Schneider M, **Rieben R**. The onset of reperfusion injury: Deposition of antibodies and complement in viable myocardium in a porcine model of acute coronary syndrome. *Molecular Immunology* 2010, 47:2275-2275.

60. Lepper PM, Djafarzadeh S, Regueira T, Shaw S, Takala J, Jakob S, **Rieben R**, Spirig R. Functional consequence of TLR2 and TLR4 induced activation of HIF-1alpha on maturation of human dendritic cells. *Swiss Medical Weekly* 2010, 140(13-14):5s.
59. Kamat P, Broillet A, Helbert A, Bettinger T, Tranquart F, Schneider M, **Rieben R**. The onset of reperfusion injury: Deposition of antibodies and complement in viable myocardium in a porcine model of acute coronary syndrome. *Molecular Immunology* 2010, 47(13):2275.
58. Kiermeir D, Vögelin E, Meoli M, Vollbach F, Jenni H, Müller S, **Rieben R**, Plock J, Banic A, Constantinescu M. Can extracorporeal whole blood perfusion help in amputated limb preservation? *Journal of Vascular Research* 2009, 46(Suppl 3):37
57. **Rieben R**. Endothelial protection attenuates ischemia reperfusion injury in transplantation and myocardial infarction. *Journal of Vascular Research* 2009 46(Suppl 3):30.
56. Kamat P, Broillet A, Helbert A, Bettinger T, Hess OM, Schneider M, **Rieben R**. Ultrasound molecular imaging of coronary endothelial P-selectin expression in a porcine model of acute myocardial ischemia and reperfusion. *Journal of Vascular Research* 2009, 46(Suppl 3):36.
55. Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, Hoeffler L, **Rieben R**. In vitro assessment of the anti-inflammatory properties of IVIGs by a complement scavenging test. *Molecular Immunology* 2008, 45(16):4182.
54. Spirig R, Millard AL, Seebach JD, **Rieben R**. The complement inhibitor low molecular weight dextran sulfate prevents TLR2-mediated activation of human natural killer cells. *Molecular Immunology* 2008, 45(16):4146.
53. Gajanayake T, Sawitzki B, Matozan K, Korchagina E, Lehmann M, Volk HD, **Rieben R**. Dextran sulfate attenuates cold ischaemia-induced innate immune response and facilitates RIB 5/2-induced long-term allograft survival. *Swiss Medical Weekly* 2008 138:39S.
52. Gajanayake T, Banz Y, Matozan K, Barandier C, Yang ZH, **Rieben R**. Dextran sulfate reduces ischaemia/reperfusion injury by modulating the activation of complement and the MAPK pathway. *Molecular Immunology* 2008, 45(16):4110-4111.
51. Gajanayake T, Matozan K, Sawitzki B, Lehmann M, Cuturi MC, Volk HD, **Rieben R**. Low molecular weight dextran sulfate site-specifically attenuates complement activation induced by ischemia/reperfusion and facilitates tolerance induction in allotransplantation. *Molecular Immunology* 2007, 44(16):3946.
50. Spirig R, van Kooten C, Obregon C, Nicod L, Daha M, **Rieben R**. Modulation of toll-like receptor mediated maturation of professional human antigen-presenting cells by the complement inhibitor low molecular weight dextran sulfate. *Molecular Immunology* 2007, 44(16):3911.
49. Banz Y, **Rieben R**, Inderbitzin D, Seiler CA, Schmid SW, Dufour JF, Smith RA, Nydegger UE, Zimmermann A, Mohacsi P, Candinas D. Immunological preconditioning, including local complement inhibition, in ABO-incompatible auxiliary partial orthotopic liver transplantation as a bridge to definitive grafting in hyperacute liver failure: First report of a successful strategy. *Molecular Immunology* 2007, 44(1-3):153-154.

48. Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P, Haeberli A, Shaw S, Smith RA, **Rieben R**. Attenuation of experimental acute myocardial infarction in pigs by Mirococept, a novel complement inhibitor derived from human complement receptor type 1. *Molecular Immunology* 2007, 44(1-3):154-154.
47. Banz Y, Berdat P, Zobrist C, Meier P, Bracht H, Jakob S, Gygax E, Jenni HJ, Boone Y, Beslac O, Mettler D, Kessler U, Shaw S, Tevæearai H, Carrel T, **Rieben R**. Addition of the complement inhibitor dextran sulfate to blood cardioplegia solution attenuates myocardial reperfusion injury associated with extracorporeal circulation in a porcine model of cardiopulmonary bypass. *Molecular Immunology* 2007, 44(1-3):154-155.
46. Banz Y, Hess OM, Korchagina EY, Robson SC, Csizmadia E, Mettler D, Haeberli A, Bovin NV, **Rieben R**. Multimeric tyrosine sulfate associates with damaged endothelium and protects from reperfusion injury through modulation of complement activation in an acute model of myocardial infarction in pigs. *Molecular Immunology* 2007, 44(1-3):155-155.
45. Gajanayake T, Banz Y, Matozan K, Barandier C, Yang ZH, **Rieben R**. Complement and MAPKs mediated inflammatory responses are reduced by dextran sulfate during ischemia/reperfusion injury. *Molecular Immunology* 2007, 44(1-3):173-174.
44. Spirig R, van Kooten C, Obregon C, Nicod L, Daha M, **Rieben R**. Inhibition of toll-like receptor induced phenotypic and functional maturation of human dendritic cells by the complement inhibitor low molecular weight dextran sulfate. *Molecular Immunology* 2007, 44(1-3):243-243.
43. Banz Y, Hess OM, Robson SC, Mettler D, Haeberli A, Smith R, **Rieben R**. Mirococept (APT070), a novel complement inhibitor, attenuates reperfusion injury in an experimental model of acute myocardial infarction in pigs. *Molecular Immunology* 2006, 43:188-189.
42. Banz Y, Berdat P, Zobrist C, Bracht H, Jenni HJ, Boone Y, Beslac O, Mettler D, Carrel T, **Rieben R**. The cytoprotectant and complement inhibitor dextran sulfate attenuates myocardial reperfusion injury in a porcine model of cardiopulmonary bypass. *Molecular Immunology* 2006, 43:189-190.
41. Baumann BC, Stussi G, Huggel K, Hawley RJ, **Rieben R**, Seebach JD. Human natural antibodies directed against endothelial cells derived from Gal-alpha(1,3)Gal knock-out pigs. *Xenotransplantation* 2005, 12:375-375.
40. **Rieben R**, Banz Y, Cung T, Korchagina E, Bovin N, Haeberli A. A novel in vitro model using whole blood to study endothelial cell protection and complement inhibition in xenotransplantation. *Xenotransplantation* 2005, 12(5):393-394.
39. Korchagina EY, Pochechueva T, Obukhova P, Imberty A, **Rieben R**, Bovin NV. Design of the blood group AB glycotope. *Glycobiology* 2004, 14(11):1096-1097.
38. Tanner H, Mohacsi R, Staehli C, Heimes T, **Rieben R**, Meier B, Hullin R. The combination of brain natriuretic peptide and C-reactive protein identifies chronic heart failure patients at high cardiovascular risk. *Eur Heart J* 2004, 25(Suppl):291.
37. Laumonier T, Matozan KM, Vanhove B, Mohacsi PJ, **Rieben R**. Endothelial cell protection with dextran sulfate: a novel strategy to prevent acute vascular rejection in hamster-to-rat cardiac xenotransplantation. *Eur Heart J* 2003, 24(Suppl):31.

36. Laumonier T, Vanhove B, Matozan KM, Mohacsi P, **Rieben R**. Endothelial cell protection with dextran sulfate: A novel strategy to prevent acute vascular rejection in cardiac xenotransplantation. *Circulation* 2003, 108(17, Suppl):308.
35. Laumonier T, Vanhove B, Matozan KM, Mohacsi PJ, **Rieben R**. Endothelial cell protection with dextran sulfate: a novel strategy to prevent acute vascular rejection in xenotransplantation. *Xenotransplantation* 2003, 10(5):518.
34. Banz Y, Cung T, Kohler A, Haerberli A, **Rieben R**. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood. *Xenotransplantation* 2003, 10:512.
33. Laumonier T, Walpen A, Matozan KM, Korchagina EY, Bovin NV, **Rieben R**. sTyr-PAA, a polymeric sulfated tyrosine, binds to endothelial cells and inhibits complement deposition in vitro and in vivo. *Mol Immunol* 2003, 40(2-4):198.
32. Walpen A, Laumonier T, Aebi C, **Rieben R**. IgM-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum. *Mol Immunol* 2003, 40(2-4):195.
31. Banz Y, Hess OM, Mettler D, Haerberli A, **Rieben R**. Local complement inhibition and endothelial cell protection with dextran sulfate significantly reduces infarct size in a pig model of myocardial infarction. *Mol Immunol* 2003, 40(2-4):189.
30. Laumonier T, Matozan KM, Vanhove B, Mohacsi PJ, **Rieben R**. Complement inhibition/endothelial cell protection: a novel strategy to prevent acute vascular rejection in xenotransplantation. *Mol Immunol* 2003, 40(2-4):188.
29. Banz Y, Hess OM, Mettler D, Mohacsi PJ, **Rieben R**. Reduction of infarct size by complement inhibition and endothelial cell protection with dextran sulfate. *Cardiovasc Med* 2003, 6:34S.
28. Laumonier T, Mohacsi PJ, Korchagina EY, Bovin NV, **Rieben R**. Low molecular weight dextran sulfate acts as an endothelial cell-protectant and prevents complement activation in xenotransplantation models. *Eur Heart J* 2002, 23:S175.
27. Walpen AJ, Mohacsi PJ, Frey C, Roos A, Daha MR, **Rieben R**. Xenoreactive anti-Gal antibodies activate both classical and alternative complement pathways. *Transplantation* 2002, 74(4):630.
26. Walpen AJ, Laumonier T, Mohacsi PJ, Korchagina EY, Bovin NV, **Rieben R**. Novel complement inhibitors for the prevention of antibody mediated complement activation. *Transplantation* 2002, 74(4):390.
25. Laumonier T, Mohacsi PJ, Korchagina EY, Bovin NV, **Rieben R**. Low molecular weight dextran sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models. *Transplantation* 2002, 74(4):129-130.
24. Walpen AJ, Laumonier T, Mohacsi PJ, Korchagina EY, Bovin NV, **Rieben R**. Novel complement inhibitors for the prevention of antibody mediated complement activation. *International Immunopharmacology*, 2002 2(9):13011-1312.
23. Laumonier T, Mohacsi PJ, Korchagina EY, Bovin NV, **Rieben R**. Assessment of an "endothelial cell protectant" in xenotransplantation models: effect of low molecular weight dextran sulfate. *International Immunopharmacology* 2002, 2(9):1309.

22. Laumonier T, Mohacsi PJ, Korchagina EY, Bovin NV, **Rieben R**. Low molecular weight dextran sulfate acts as an "endothelial cell-protectant" and prevents complement activation in xenotransplantation models. *Swiss Med Wkly* 2002, 132(Suppl 129):31.
21. Walpen AJ, Laumonier T, Mohacsi PJ, Bovin NV, **Rieben R**. In vitro analysis of novel complement inhibitors. *Swiss Med Wkly* 2002, 132 (Suppl. 129):31.
20. Laumonier T, Grünenfelder S, Korchagina E, Bovin N, Mohacsi P, **Rieben R**. Low molecular weight dextran sulfate acts as an 'endothelial cell-protectant' and prevents complement activation as well as ischemia/reperfusion injury in vitro. *Mol Immunol* 2001, 38(2-3):105-106.
19. Walpen A, Mohacsi P, **Rieben R**. In vitro xenotransplantation models for the analysis of novel, pathway-specific complement inhibitors. *Mol Immunol* 2001, 38(2-3):127.
18. Laumonier T, Gruenenfelder S, Korchagina E, Bovin N, Mohacsi P, **Rieben R**. Low molecular weight dextran sulfate prevents complement activation and acts as an "endothelial cell-protectant" in xenotransplantation and ischemia/reperfusion models in vitro. *Xenotransplantation* 2001, 8(Suppl. 1):307.
17. Walpen AJ, Frey C, Mohacsi P, **Rieben R**. In vitro xenotransplantation model for the analysis of novel, pathway-specific complement inhibitors. *Xenotransplantation* 2001, 8(Suppl. 1):309.
16. Always IPJ, Basker M, Bühler L, **Rieben R**, Harper D, Appel JZ, Awwad M, Down J, White-Scharf M, Sachs DH, Thall A, Cooper DKC. Porcine hematopoietic progenitor cells are rapidly cleared by the phagocytic reticuloendothelial system in baboons. *Transplantation* 2000, 69:S420.
15. **Rieben R**, Matozan-Dzelalija K, Mohacsi P. Komplementinhibitoren zur Behandlung der (hyper-)akuten vaskulären Abstoßung: In vitro und in vivo Resultate mit IVIgM und Dextransulfat. *Kardiovaskuläre Medizin* 2000, 3 (Suppl. 2):50S.
14. **Rieben R**, Dzelalija K, Mohacsi P. Complement inhibitors to prevent (hyper-)acute vascular rejection: in vitro and in vivo results with IgM-enriched IVIG, C1-inh, and 5'000 d dextran sulfate. *Immunopharmacology* 2000, 49(1-2):71.
13. Walpen A, Mohacsi P, **Rieben R**. Lysis of rabbit erythrocytes by human serum requires anti-Gal antibody, the alternative complement pathway, and C1q. *Immunopharmacology* 2000, 49(1-2):91.
12. **Rieben R**. IgM-enriched intravenous immunoglobulin: Anti-inflammatory therapy by complement inhibition. *Shock* 2000, 13:92.
11. Mohacsi P, **Rieben R**, Nydegger UE. Immunosuppression in ABO-incompatible transplantation. *Transpl Proc* 2001, 33(3):2223-2224.
10. **Rieben R**, Wuillemin WA, Nydegger UE, Mohacsi PJ. IVIgM, C1-inhibitor, and 5'000 d dextran sulfate: Antiinflammatory therapy by inhibition of complement and contact systems. *Journal für Anästhesie und Intensivbehandlung* 2000, 7(1):165-166.
9. **Rieben R**, Fiorante P, Banz Y, Mazmanian M, Macchiarini P, Mohacsi P. Effects of 5 kD dextran sulfate in vitro and ex vivo in xenotransplantation. *Mol Immunol* 1999, 36(4/5):312.

8. Buonomano R, Tinguely C, **Rieben R**, Tempia A, Gaschen S, Nydegger U. Evaluation of a titer of natural human anti-Gal alpha1-3 Gal (anti-diGal) antibodies of 100 females and 100 males sera by using rabbit erythrocytes. *Infus Ther Transfus Med* 1998, 25(Suppl 1):75.
7. **Rieben R**, Dzelalija KM, Korchagina EY, Bovin NV, Mohacsi PJ. Antikörperantwort nach akzidenteller ABO-inkompatibler Herz-Allotransplantation. *Infus Ther Transfus Med* 1998. 25(Suppl 1):75.
6. **Rieben R**, Gerritsen AF, Nydegger UE, Daha MR. Blocking of complement activation by intravenously applicable IgG, -M, and -A preparations: analysis of the efficacy of C4b- and C3b-scavenging. *Exp Clin Immunogenet* 1997, 14: 104.
5. **Rieben R**, Gerritsen AF, Daha MR Comparison of IgG, IgA, and IgM preparations for their capacity to scavenge the activated complement components C4b and C3b. *Shock* 1997, 7(Suppl):159.
4. **Rieben R**, von Allmen E, Nydegger UE. New synthetic ABO-immunoabsorbents: In vitro evaluation of efficacy and biocompatibility. *Transfusion* 1993, 33(Suppl.):24.
3. Sandberg Tschopp A, Horber F, Lerut J, **Rieben R**, Nydegger UE. Anti-A/B histo-blood group IgM/G/A serum quantities to monitor outcome of kidney transplantation (letter). *Transfus Sci* 1992; 13:455-456.
2. **Rieben R**, Nydegger UE. Antibodies to human histo-blood group substances A and B. *Fed Am Soc Exp Biol* 1991; J5(4):A647.
1. **Rieben R**, Mueller U, Blaser K. Quantitation and epitope-characterization of IgE and IgG antibodies to bee-venom phospholipase A2. *Int Arch Allergy Appl Immunol* 1987; 83(Suppl 1):40.